These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 38629815

  • 1. A pictorial view on false positive findings of 68Ga-PSMA-11 PET/CT and their prognostic value in patients with prostate carcinoma after radical prostatectomy and undetectable PSA values.
    Dancheva Z, Chausheva S, Stoeva T, Dyankova M, Yordanova T, Chaushev B, Marinov R, Nikolov V, Abushev P, Todorov G, Dimitrova E, Klisarova A, Anakievski D.
    Hell J Nucl Med; 2024; 27(1):16-26. PubMed ID: 38629815
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 4. The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy.
    Wang Y, Dong L, Zhao H, Li L, Huang G, Xue W, Liu J, Chen R.
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2484-2494. PubMed ID: 38514483
    [Abstract] [Full Text] [Related]

  • 5. Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy.
    Miksch J, Bottke D, Krohn T, Thamm R, Bartkowiak D, Solbach C, Bolenz C, Beer M, Wiegel T, Beer AJ, Prasad V.
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2339-2347. PubMed ID: 32157427
    [Abstract] [Full Text] [Related]

  • 6. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
    Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [Abstract] [Full Text] [Related]

  • 7. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.
    Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [Abstract] [Full Text] [Related]

  • 8. Comparison of digital and analog [68Ga]Ga-PSMA-11 PET/CT for detecting post-prostatectomy biochemical recurrence in prostate cancer patients: a prospective study.
    Kim YI, Lee DY, Sung C, Lee SJ, Oh SJ, Oh JS, Yoon S, Lee JL, Lim B, Suh J, Park J, You D, Jeong IG, Hong JH, Ahn H, Kim CS, Ryu JS.
    Sci Rep; 2024 Jul 01; 14(1):14989. PubMed ID: 38951530
    [Abstract] [Full Text] [Related]

  • 9. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.
    Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan 01; 46(1):11-19. PubMed ID: 29905907
    [Abstract] [Full Text] [Related]

  • 10. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
    Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan 01; 46(1):31-39. PubMed ID: 30350010
    [Abstract] [Full Text] [Related]

  • 11. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.
    van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.
    BJU Int; 2019 Jul 01; 124(1):62-68. PubMed ID: 30074667
    [Abstract] [Full Text] [Related]

  • 12. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses.
    Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F.
    Urol Oncol; 2022 Jan 01; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [Abstract] [Full Text] [Related]

  • 13. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
    Rogic I, Golubic AT, Zuvic M, Smitran T, Jukic N, Gamulin M, Kastelan Z, Huic D.
    Nucl Med Rev Cent East Eur; 2024 Jan 01; 27(0):6-12. PubMed ID: 38680016
    [Abstract] [Full Text] [Related]

  • 14. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.
    J Nucl Med; 2015 Aug 01; 56(8):1185-90. PubMed ID: 26112024
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Direct Patlak Reconstruction of [68Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study.
    Rasul S, Geist BK, Einspieler H, Fajkovic H, Shariat SF, Schmitl S, Mitterhauser M, Bartosch R, Langsteger W, Baltzer PAT, Beyer T, Ferrara D, Haug AR, Hacker M, Rausch I.
    Int J Mol Sci; 2023 Sep 05; 24(18):. PubMed ID: 37761975
    [Abstract] [Full Text] [Related]

  • 17. The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax.
    Yilmaz U, Komek H, Can C, Altindag S.
    Ann Nucl Med; 2019 Aug 05; 33(8):545-553. PubMed ID: 31069696
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
    McCarthy M, Francis R, Tang C, Watts J, Campbell A.
    Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448
    [Abstract] [Full Text] [Related]

  • 20. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
    Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C.
    Radiat Oncol; 2018 Mar 02; 13(1):37. PubMed ID: 29499730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.